LYELL IMMUNOPHARMA INC (LYEL)

US55083R1041 - Common Stock

0.645  +0.01 (+0.78%)

After market: 0.645 0 (0%)

Free users can only see 4 years or quarters

Examples of complete financials are available for MSFT and AAPL.

Please register or login for additional data.

TTM
(2024-9-30)
2023
(2023-12-31)
2022
(2022-12-31)
2021
(2021-12-31)
2020
(2020-12-31)
Revenue
63.00K130.00K84.68M10.65M7.76M
Operating Expenses
217.18M247.14M271.74M225.12M219.69M
Research and Development
174.51M185.72M164.32M134.98M182.24M
Selling, General, and Administrative Expenses
50.69M66.98M117.31M89.06M46.88M
Operating Income
-217.12M-247.01M-187.06M-214.47M-211.94M
Interest Income/Expense
26.23M23.45M5.99M910.00K5.94M
Other Income/Expense
-104.00K1.85M2.95M100.00K1.53M
Non Recurring Items
-13.00M-12.92M-5.00M-36.75MN/A
Income Before Taxes
-203.99M-234.63M-183.12M-250.22M-204.47M
Net Income
-203.99M-234.63M-183.12M-250.22M-204.47M
EBITDA
-197.45M-226.76M-169.04M-200.85M-207.65M
 
Per Share Data
EPS Diluted Total Ops
-0.80-0.93-0.73-1.03-0.84
Non GAAP EPS
-0.79-0.78-0.75N/AN/A
 
Statistics
Profit Margin
-323792.06%-180486.15%-216.25%-2349.48%-2634.92%
Operating Profit Margin
-344628.57%-190006.15%-220.90%-2013.80%-2731.19%

All data in USD

Charts